Healthcare Industry News: HSMN NewsFeed
News Release - February 12, 2018
Regeneron Announces Appointment of Marion McCourt as Senior Vice President and Head of CommercialTARRYTOWN, N.Y., Feb. 12, 2018 -- (Healthcare Sales & Marketing Network) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today announced the appointment of Marion McCourt as the Senior Vice President and Head of Commercial. Ms. McCourt joined Regeneron today to lead all aspects of product commercialization for Regeneron's currently approved medicines and development-stage pipeline.
"Marion is an accomplished biopharmaceutical executive who brings a track record of success in commercializing products and leading commercial teams," said Leonard S. Schleifer, MD, PhD, President and Chief Executive Officer of Regeneron. "With several marketed therapies for serious diseases and more than 15 late-stage programs that could result in new approvals or indications, Marion will play a critical role in shaping Regeneron's future and ensuring our innovative medicines reach patients in need."
Ms. McCourt has more than two decades of broad experience in biopharmaceutical management with an emphasis on commercial strategy and execution. She began her biopharmaceutical career with AstraZeneca where she held positions of increasing responsibility over 12 years, ultimately becoming Chief Operating Officer for AstraZeneca U.S. She then held commercial leadership roles at Amgen including Vice President in U.S. Commercial Operations and Vice President and General Manager responsible for the company's bone health and primary care business unit. Most recently, Ms. McCourt served as Chief Operating Officer of Medivation until its acquisition by Pfizer in 2016, and as President and Chief Operating Officer of Axovant, a clinical-stage biopharmaceutical company. She holds a B.S. in Biology from Lafayette College.
"I have long admired Regeneron for its science-driven culture and patient-first mindset," said Ms. McCourt. "I'm delighted to join Regeneron during this exciting period of growth. Regeneron products have the potential to help so many people with serious diseases, and I'm looking forward to working with the team to fully maximize all these unique opportunities."
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to six FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, heart disease, allergic and inflammatory diseases, pain, cancer, infectious diseases and rare diseases.
Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuiteŽ technologies, such as VelocImmuneŽ which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.
For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.
Source: Regeneron Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsRegeneron Announces Approval of DUPIXENT(R) (dupilumab) in Japan for the Treatment of Atopic Dermatitis
Regeneron Announces FDA Acceptance of sBLA Filing for 12-Week Dosing of EYLEA(R) (aflibercept) Injection for Patients with Wet AMD
Regeneron Provides Update on EYLEA(R) (aflibercept) Injection and Nesvacumab (Ang2 Antibody) Combination Program